Lapatinib

Generic Name: Lapatinib

Brand Names: Tykerb, Tyverb

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₂₆ClFN_₄O_₄S

CAS Number: 231277-92-2

Unique Ingredient Identifier: 0VUA21238F

Background: Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.

Indication: Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

Associated Conditions: Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer

Associated Therapies: -

Clinical Trials

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Foretinib
Drug: Lapatinib

First Posted Date: 2010-06-07

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 19

Registration Number: NCT01138384

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada

and more 2 locations

GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

Phase 1

Terminated

Conditions: Breast Cancer
Neoplasm Metastasis

Interventions: Drug: Vorinostat
Drug: Lapatinib

First Posted Date: 2010-05-07

Last Posted Date: 2019-11-13

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 12

Registration Number: NCT01118975

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

Lapatinib With Sirolimus or Metformin

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Lapatinib
Drug: Metformin
Drug: Sirolimus

First Posted Date: 2010-03-16

Last Posted Date: 2015-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT01087983

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: BMS-690514
Drug: Lapatinib
Drug: Letrozole

First Posted Date: 2010-02-15

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4

Registration Number: NCT01068704

Locations: 🇺🇸
Texas Oncology-Abilene, Abilene, Texas, United States
🇺🇸
Texas Oncology-Beaumont, Beaumont, Texas, United States
🇺🇸
Us Oncology Central Pharmacy, Fort Worth, Texas, United States

and more 2 locations

Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: lapatinib
Drug: docetaxel

First Posted Date: 2010-01-08

Last Posted Date: 2012-09-25

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 17

Registration Number: NCT01044485

Locations: 🇫🇷
Centre Georges François Leclerc, Dijon, Bourgogne, France

Lapatinib in Combination With Vinorelbine

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: Lapatinib
Drug: Vinorelbine
Drug: Capecitabine

First Posted Date: 2009-11-16

Last Posted Date: 2017-05-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 112

Registration Number: NCT01013740

Locations: 🇪🇸
Novartis Investigative Site, Zamora, Spain

ELBA: Exemestane and Lapatinib in Advanced Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: exemestane
Drug: lapatinib

First Posted Date: 2009-11-01

Last Posted Date: 2012-07-13

Lead Sponsor: National Cancer Institute, Naples

Registration Number: NCT01005641

Locations: 🇮🇹
Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy
🇮🇹
Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
🇮🇹
Ospedale S. Luca ASL SA 3, Vallo della Lucania, Italy

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Lapatinib
Drug: Letrozole
Drug: Trastuzumab

First Posted Date: 2009-10-22

Last Posted Date: 2023-06-18

Lead Sponsor: Baylor Breast Care Center

Target Recruit Count: 128

Registration Number: NCT00999804

Locations: 🇺🇸
Baylor College of Medicine Lester and Sue Smith Breast Center, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States

and more 5 locations